Production (Stage)
Zenas BioPharma, Inc.
ZBIO
$11.43
-$0.02-0.18%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 54.18% | 140.75% | 258.53% | 126.65% | 47.55% |
| Gross Profit | -10.02% | -116.27% | -182.49% | -126.65% | -47.55% |
| SG&A Expenses | 151.67% | 162.92% | 48.37% | 47.74% | 31.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 71.62% | 144.65% | 185.09% | 110.00% | 44.49% |
| Operating Income | -35.36% | -124.48% | -215.05% | -110.00% | -44.49% |
| Income Before Tax | -21.50% | -114.84% | -208.42% | -30.74% | -45.57% |
| Income Tax Expenses | -- | 42.52% | -- | -- | -- |
| Earnings from Continuing Operations | -20.77% | -113.95% | -208.42% | -30.74% | -45.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.77% | -113.95% | -208.42% | -30.74% | -45.57% |
| EBIT | -35.36% | -124.48% | -215.05% | -110.00% | -44.49% |
| EBITDA | -35.44% | -124.62% | -214.86% | -110.13% | -44.53% |
| EPS Basic | 95.51% | 92.13% | -307.18% | -1,409.45% | -41.65% |
| Normalized Basic EPS | 95.37% | 92.00% | -121.66% | -98.59% | -38.11% |
| EPS Diluted | 95.51% | 92.13% | -356.12% | -1,411.08% | -41.65% |
| Normalized Diluted EPS | 95.37% | 92.00% | -126.74% | -98.59% | -38.11% |
| Average Basic Shares Outstanding | 2,589.71% | 2,620.21% | 400.53% | 2.23% | 2.77% |
| Average Diluted Shares Outstanding | 2,589.71% | 2,620.21% | 305.48% | 2.23% | 2.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |